Wedbush Forecasts MannKind’s FY2025 Earnings (NASDAQ:MNKD)

MannKind Corporation (NASDAQ:MNKD) – Investment analysts at Wedbush upped their FY2025 earnings per share estimates for shares of MannKind in a report issued on Monday, November 10th. Wedbush analyst Y. Zhong now forecasts that the biopharmaceutical company will post earnings per share of $0.15 for the year, up from their previous estimate of $0.04. The consensus estimate for MannKind’s current full-year earnings is $0.10 per share. Wedbush also issued estimates for MannKind’s Q4 2025 earnings at $0.02 EPS.

Other analysts have also recently issued reports about the stock. Oppenheimer raised their price target on shares of MannKind from $12.00 to $15.00 and gave the company an “outperform” rating in a report on Friday, September 5th. Royal Bank Of Canada decreased their target price on shares of MannKind from $8.00 to $7.50 and set an “outperform” rating for the company in a research report on Tuesday. HC Wainwright reaffirmed a “buy” rating on shares of MannKind in a report on Monday. Zacks Research raised MannKind from a “strong sell” rating to a “hold” rating in a research report on Monday, October 6th. Finally, Leerink Partners began coverage on MannKind in a report on Friday, October 10th. They set an “outperform” rating and a $9.00 price objective for the company. One research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and two have given a Hold rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $10.50.

MannKind Price Performance

MNKD opened at $5.25 on Wednesday. The firm has a market capitalization of $1.61 billion, a PE ratio of 47.73 and a beta of 1.11. The business’s 50-day moving average is $5.44 and its two-hundred day moving average is $4.58. MannKind has a 1 year low of $3.38 and a 1 year high of $7.44.

MannKind (NASDAQ:MNKD) last released its quarterly earnings results on Wednesday, November 5th. The biopharmaceutical company reported $0.03 EPS for the quarter, topping the consensus estimate of $0.01 by $0.02. The firm had revenue of $82.13 million during the quarter, compared to analyst estimates of $80.47 million. MannKind had a negative return on equity of 32.60% and a net margin of 10.87%.The business’s revenue for the quarter was up 17.1% compared to the same quarter last year. During the same period in the previous year, the company posted $0.04 EPS.

Institutional Investors Weigh In On MannKind

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Vanguard Group Inc. grew its position in MannKind by 7.9% during the first quarter. Vanguard Group Inc. now owns 17,322,179 shares of the biopharmaceutical company’s stock valued at $87,131,000 after buying an additional 1,263,622 shares during the period. Geode Capital Management LLC increased its holdings in MannKind by 12.3% in the 2nd quarter. Geode Capital Management LLC now owns 7,617,583 shares of the biopharmaceutical company’s stock worth $28,494,000 after acquiring an additional 831,478 shares in the last quarter. Millennium Management LLC raised its position in MannKind by 68.9% during the first quarter. Millennium Management LLC now owns 5,822,590 shares of the biopharmaceutical company’s stock worth $29,288,000 after acquiring an additional 2,375,198 shares during the period. Qube Research & Technologies Ltd raised its position in MannKind by 25.5% during the second quarter. Qube Research & Technologies Ltd now owns 4,065,904 shares of the biopharmaceutical company’s stock worth $15,206,000 after acquiring an additional 825,608 shares during the period. Finally, Nuveen LLC purchased a new position in MannKind during the first quarter valued at $17,011,000. Institutional investors and hedge funds own 49.55% of the company’s stock.

Insider Transactions at MannKind

In other MannKind news, insider Stuart A. Tross sold 47,000 shares of the company’s stock in a transaction on Tuesday, September 16th. The shares were sold at an average price of $5.34, for a total value of $250,980.00. Following the sale, the insider directly owned 1,032,013 shares of the company’s stock, valued at approximately $5,510,949.42. This represents a 4.36% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 3.00% of the stock is owned by corporate insiders.

MannKind Company Profile

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults.